{"id":3172,"date":"2024-11-28T17:30:00","date_gmt":"2024-11-28T09:30:00","guid":{"rendered":"https:\/\/www.junshipharma.com\/?p=3172"},"modified":"2024-11-29T15:37:43","modified_gmt":"2024-11-29T07:37:43","slug":"junshi-biosciences-announces-four-new-indications-of-toripalimab-included-in-the-nrdl","status":"publish","type":"post","link":"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-four-new-indications-of-toripalimab-included-in-the-nrdl\/","title":{"rendered":"Junshi Biosciences Announces Four New Indications of Toripalimab Included in the NRDL"},"content":{"rendered":"\n

SHANGHAI, China, November 28, 2024 — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that four new indications of the company\u2019s product toripalimab injection (trade name: TUOYI\u00ae, product code: JS001) were successfully included in Category of the National Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (Year 2024) (the \u201cNRDL\u201d). The new edition of the NRDL will be officially come into effect on 1 January 2025.<\/p>\n\n\n\n

Up till now, ten approved indications of TUOYI\u00ae in Chinese mainland were all included in the NRDL and it is the only anti-PD-1 monoclonal antibody included in the NRDL for the treatment of melanoma, perioperative treatment of non-small cell lung cancer (\u201cNSCLC\u201d), treatment of renal carcinoma and treatment of triple-negative breast cancer (\u201cTNBC\u201d).<\/p>\n\n\n\n

Indications:<\/p>\n\n\n\n

    \n
  1. Treatment for unresectable or metastatic melanoma after failure of standard systemic therapy;<\/li>\n\n\n\n
  2. Treatment for locally advanced or metastatic urothelial carcinoma that failed platinum containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy;<\/li>\n\n\n\n
  3. Treatment for patients with recurrent\/metastatic nasopharyngeal carcinoma (\u201cNPC\u201d) after failure of at least two lines of prior systemic therapy;<\/li>\n\n\n\n
  4. First-line treatment for patients with locally recurrent or metastatic NPC;<\/li>\n\n\n\n
  5. First-line treatment for patients with unresectable locally advanced\/recurrent or metastatic esophageal squamous cell carcinoma;<\/li>\n\n\n\n
  6. First-line treatment for patients with EGFR mutation-negative and ALK mutation-negative, unresectable, locally advanced or metastatic non-squamous NSCLC;<\/li>\n\n\n\n
  7. The product in combination with chemotherapy as perioperative treatment and subsequently, monotherapy as adjuvant therapy for the treatment of adult patients with resectable stage IIIA-IIIB NSCLC;<\/li>\n\n\n\n
  8. The product in combination with axitinib for the first-line treatment of patients with medium to high risk unresectable or metastatic renal cell carcinoma; <\/li>\n\n\n\n
  9. The product in combination with etoposidein plus platinum for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC);<\/li>\n\n\n\n
  10. The product in combination with paclitaxel for injection (albumin-bound) for the first-line treatment of recurrent or metastatic TNBC with a well-validated test to evaluate PD-L1 positive (CPS \u2265 1).<\/li>\n<\/ol>\n\n\n\n

    Items 7 to 10 are new indications included in the NRDL.<\/p>\n\n\n\n

    In addition, the successful inclusion of the 4 new indications of TUOYI\u00ae in the NRDL is the first time that the NRDL included immunotherapy for perioperative NSCLC, renal carcinoma, small cell lung cancer and TNBC.<\/p>\n","protected":false},"excerpt":{"rendered":"

    4 new indications of toripalimab were successfully included in the 2024 NRDL<\/p>\n","protected":false},"author":6,"featured_media":3161,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22],"tags":[],"class_list":["post-3172","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"\nJunshi Biosciences Announces Four New Indications of Toripalimab Included in the NRDL - \u541b\u5b9e\u751f\u7269<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-four-new-indications-of-toripalimab-included-in-the-nrdl\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Announces Four New Indications of Toripalimab Included in the NRDL - \u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"og:description\" content=\"4 new indications of toripalimab were successfully included in the 2024 NRDL\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-four-new-indications-of-toripalimab-included-in-the-nrdl\/\" \/>\n<meta property=\"og:site_name\" content=\"\u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-28T09:30:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-29T07:37:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2024\/11\/\u5c01\u9762\u56fe.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2350\" \/>\n\t<meta property=\"og:image:height\" content=\"1000\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u5389, \u667a\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u5389, \u667a\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-four-new-indications-of-toripalimab-included-in-the-nrdl\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-four-new-indications-of-toripalimab-included-in-the-nrdl\/\"},\"author\":{\"name\":\"\u5389, \u667a\",\"@id\":\"https:\/\/www.junshipharma.com\/#\/schema\/person\/8f1f048789146c2f6f01066f181883a4\"},\"headline\":\"Junshi Biosciences Announces Four New Indications of Toripalimab Included in the NRDL\",\"datePublished\":\"2024-11-28T09:30:00+00:00\",\"dateModified\":\"2024-11-29T07:37:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-four-new-indications-of-toripalimab-included-in-the-nrdl\/\"},\"wordCount\":385,\"publisher\":{\"@id\":\"https:\/\/www.junshipharma.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-four-new-indications-of-toripalimab-included-in-the-nrdl\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2024\/11\/\u5c01\u9762\u56fe.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-four-new-indications-of-toripalimab-included-in-the-nrdl\/\",\"url\":\"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-four-new-indications-of-toripalimab-included-in-the-nrdl\/\",\"name\":\"Junshi Biosciences Announces Four New Indications of Toripalimab Included in the NRDL - \u541b\u5b9e\u751f\u7269\",\"isPartOf\":{\"@id\":\"https:\/\/www.junshipharma.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-four-new-indications-of-toripalimab-included-in-the-nrdl\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-four-new-indications-of-toripalimab-included-in-the-nrdl\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2024\/11\/\u5c01\u9762\u56fe.jpg\",\"datePublished\":\"2024-11-28T09:30:00+00:00\",\"dateModified\":\"2024-11-29T07:37:43+00:00\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-four-new-indications-of-toripalimab-included-in-the-nrdl\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-four-new-indications-of-toripalimab-included-in-the-nrdl\/#primaryimage\",\"url\":\"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2024\/11\/\u5c01\u9762\u56fe.jpg\",\"contentUrl\":\"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2024\/11\/\u5c01\u9762\u56fe.jpg\",\"width\":2350,\"height\":1000},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.junshipharma.com\/#website\",\"url\":\"https:\/\/www.junshipharma.com\/\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"description\":\"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002\",\"publisher\":{\"@id\":\"https:\/\/www.junshipharma.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.junshipharma.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.junshipharma.com\/#organization\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"url\":\"https:\/\/www.junshipharma.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.junshipharma.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"contentUrl\":\"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"width\":2147,\"height\":795,\"caption\":\"\u541b\u5b9e\u751f\u7269\"},\"image\":{\"@id\":\"https:\/\/www.junshipharma.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.junshipharma.com\/#\/schema\/person\/8f1f048789146c2f6f01066f181883a4\",\"name\":\"\u5389, \u667a\",\"url\":\"https:\/\/www.junshipharma.com\/en\/author\/zhi_li\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Junshi Biosciences Announces Four New Indications of Toripalimab Included in the NRDL - \u541b\u5b9e\u751f\u7269","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-four-new-indications-of-toripalimab-included-in-the-nrdl\/","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Announces Four New Indications of Toripalimab Included in the NRDL - \u541b\u5b9e\u751f\u7269","og_description":"4 new indications of toripalimab were successfully included in the 2024 NRDL","og_url":"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-four-new-indications-of-toripalimab-included-in-the-nrdl\/","og_site_name":"\u541b\u5b9e\u751f\u7269","article_published_time":"2024-11-28T09:30:00+00:00","article_modified_time":"2024-11-29T07:37:43+00:00","og_image":[{"width":2350,"height":1000,"url":"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2024\/11\/\u5c01\u9762\u56fe.jpg","type":"image\/jpeg"}],"author":"\u5389, \u667a","twitter_card":"summary_large_image","twitter_misc":{"Written by":"\u5389, \u667a","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-four-new-indications-of-toripalimab-included-in-the-nrdl\/#article","isPartOf":{"@id":"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-four-new-indications-of-toripalimab-included-in-the-nrdl\/"},"author":{"name":"\u5389, \u667a","@id":"https:\/\/www.junshipharma.com\/#\/schema\/person\/8f1f048789146c2f6f01066f181883a4"},"headline":"Junshi Biosciences Announces Four New Indications of Toripalimab Included in the NRDL","datePublished":"2024-11-28T09:30:00+00:00","dateModified":"2024-11-29T07:37:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-four-new-indications-of-toripalimab-included-in-the-nrdl\/"},"wordCount":385,"publisher":{"@id":"https:\/\/www.junshipharma.com\/#organization"},"image":{"@id":"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-four-new-indications-of-toripalimab-included-in-the-nrdl\/#primaryimage"},"thumbnailUrl":"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2024\/11\/\u5c01\u9762\u56fe.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-four-new-indications-of-toripalimab-included-in-the-nrdl\/","url":"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-four-new-indications-of-toripalimab-included-in-the-nrdl\/","name":"Junshi Biosciences Announces Four New Indications of Toripalimab Included in the NRDL - \u541b\u5b9e\u751f\u7269","isPartOf":{"@id":"https:\/\/www.junshipharma.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-four-new-indications-of-toripalimab-included-in-the-nrdl\/#primaryimage"},"image":{"@id":"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-four-new-indications-of-toripalimab-included-in-the-nrdl\/#primaryimage"},"thumbnailUrl":"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2024\/11\/\u5c01\u9762\u56fe.jpg","datePublished":"2024-11-28T09:30:00+00:00","dateModified":"2024-11-29T07:37:43+00:00","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-four-new-indications-of-toripalimab-included-in-the-nrdl\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-four-new-indications-of-toripalimab-included-in-the-nrdl\/#primaryimage","url":"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2024\/11\/\u5c01\u9762\u56fe.jpg","contentUrl":"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2024\/11\/\u5c01\u9762\u56fe.jpg","width":2350,"height":1000},{"@type":"WebSite","@id":"https:\/\/www.junshipharma.com\/#website","url":"https:\/\/www.junshipharma.com\/","name":"\u541b\u5b9e\u751f\u7269","description":"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002","publisher":{"@id":"https:\/\/www.junshipharma.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.junshipharma.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.junshipharma.com\/#organization","name":"\u541b\u5b9e\u751f\u7269","url":"https:\/\/www.junshipharma.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.junshipharma.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","contentUrl":"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","width":2147,"height":795,"caption":"\u541b\u5b9e\u751f\u7269"},"image":{"@id":"https:\/\/www.junshipharma.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.junshipharma.com\/#\/schema\/person\/8f1f048789146c2f6f01066f181883a4","name":"\u5389, \u667a","url":"https:\/\/www.junshipharma.com\/en\/author\/zhi_li\/"}]}},"_links":{"self":[{"href":"https:\/\/www.junshipharma.com\/en\/wp-json\/wp\/v2\/posts\/3172"}],"collection":[{"href":"https:\/\/www.junshipharma.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.junshipharma.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.junshipharma.com\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.junshipharma.com\/en\/wp-json\/wp\/v2\/comments?post=3172"}],"version-history":[{"count":2,"href":"https:\/\/www.junshipharma.com\/en\/wp-json\/wp\/v2\/posts\/3172\/revisions"}],"predecessor-version":[{"id":3177,"href":"https:\/\/www.junshipharma.com\/en\/wp-json\/wp\/v2\/posts\/3172\/revisions\/3177"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.junshipharma.com\/en\/wp-json\/wp\/v2\/media\/3161"}],"wp:attachment":[{"href":"https:\/\/www.junshipharma.com\/en\/wp-json\/wp\/v2\/media?parent=3172"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.junshipharma.com\/en\/wp-json\/wp\/v2\/categories?post=3172"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.junshipharma.com\/en\/wp-json\/wp\/v2\/tags?post=3172"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}